Stay updated with breaking news from Previously Treated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of...
Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve PatientsNo New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to ModerateEnrollment of Patients Naïve to or Previously Treated with a KRA...
1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related interstitial lung disease was more common with patients receiving trastuzumab deruxtecan. Evidence Rating Level: 1 (Excellent) Study Rundown: A large proportion of breast cancers are characterized by overexpression of HER2 receptors. While first-line therapy for
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global...
-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for... | April 27, 2023